Today: 3 June 2026
OCBC share price rises as DBS profit miss sharpens focus on Singapore bank earnings
9 February 2026
2 mins read

OCBC share price rises as DBS profit miss sharpens focus on Singapore bank earnings

Singapore, Feb 9, 2026, 15:03 SGT — Regular session

  • OCBC shares edged up about 0.9% in afternoon deals.
  • DBS shares slid after fourth-quarter profits came in below expectations, triggering the sell-off.
  • OCBC is up next, with investors closely watching for any signs of margin pressure and potential signals on dividends.

Oversea-Chinese Banking Corp stock edged up Monday, adding roughly 0.9%—that’s 19 Singapore cents—to close at S$21.42. OCBC outpaced its peers as investors shifted into Singapore’s bank stocks ahead of a busy earnings period. DBS, by comparison, trailed the pack.

Timing matters now. DBS opened the local earnings season with a weaker quarter, and investors are left to decide: Is this a temporary miss, or is it the start of more pressure on bank profits?

OCBC has two big concerns at the moment: shrinking margins and mounting payout demands. A fall in interest rates would eat into the bank’s loan spreads. Meanwhile, with the stock at all-time highs, investors are pushing harder for larger dividends and more aggressive capital returns.

DBS missed expectations, posting a 10% slide in fourth-quarter net profit. The stock slipped 1.1%. That’s despite the Straits Times Index tacking on 0.6%. The lender’s net interest margin narrowed to 1.93% as local rates eased, according to the bank. But DBS did boost its ordinary dividend and rolled out a capital return dividend, saying those payouts will continue through financial years 2026 and 2027. CGS International analysts Tay Wee Kuang and Lim Siew Khee pointed to weaker-than-hoped trading income from markets. CEO Tan Su Shan warned investors to “buckle up” for a volatile year. Reuters

OCBC shares picked up steam, but not thanks to any bank-specific catalyst. The move looked like a sector rotation—investors rotated out of DBS following its earnings, and OCBC ended up catching some of that flow. Traders were searching for the next name that could budge.

Next up: OCBC. Investors are zeroed in on this one, hunting for signs that the bank’s interest income has topped out. The big question—can growth from wealth management and market-related fees make up the difference?

Dividend talk is picking up. DBS made its position on capital return dividends unmistakable, signaling to competitors that they’ll have to outline strategies for surplus capital if profits start to dip.

Even so, the risk is plain enough: If rates fall faster than banks are counting on, or loan appetite slows while deposit battles heat up, profit projections can change fast—and those dividend hopes could get cut down.

Credit quality is still a worry. Singapore banks carry a lot of weight in corporate and property loans—if bad-loan provisions jump, any gains elsewhere could evaporate quickly. One sharp rise, and markets might waste no time baking in a tougher cycle.

OCBC will post its 2025 full-year results on Feb. 25 before the market opens, an SGX filing shows. Shareholders are set to focus on what management says about margins and capital returns—signals that might decide whether Monday’s gain in the stock holds in the days ahead.

Stock Market Today

  • AstraZeneca Shares Dip 10.6% in 3 Months Despite Pipeline Growth Prospects
    June 3, 2026, 3:57 PM EDT. AstraZeneca (LSE:AZN) shares have fallen 10.6% over the past three months amid cooling momentum, although the stock remains up 24.8% over the past year. The company, valued at about £204.9 billion with annual revenues of $60.4 billion, shows a 44.6% intrinsic value discount against its current price of £132.10. Analysts estimate a fair value of £163.06, indicating the stock could be about 19% undervalued based on a 7.2% discount rate. AstraZeneca's late-stage pipeline, particularly in oncology and rare diseases, could generate over $10 billion in peak revenue, driving future growth. However, risks include government price controls and biosimilar competition. The current price-to-earnings ratio of 26.5x exceeds peers but remains below a fair ratio of 35.3x, suggesting potential valuation risks if sentiment declines further.

Latest articles

Oklo Stock Is Getting Hit. The Insider-Sale Filing Traders Are Watching

Oklo Stock Is Getting Hit. The Insider-Sale Filing Traders Are Watching

3 June 2026
Oklo plunged about 10% to $65.89 after a June 2 SEC filing revealed 200,000 Class A shares sold June 1 under a pre-arranged insider-trading plan tied to CEO Jacob DeWitte, triggering a sharper drop than peers as investors reacted to the insider-sale disclosure despite ongoing U.S. nuclear fuel-supply momentum and recent government selection for advanced reactor fuel talks.
Apple Shares Slip Ahead of Key AI Event

Apple Shares Slip Ahead of Key AI Event

3 June 2026
Apple shares slid 1.8% to $309.67 as investors grew cautious ahead of the June 8 WWDC, where Apple is expected to reveal AI advancements; UBS sees limited upside from the event, while Morgan Stanley and BofA are more bullish, making the keynote a key test for Apple’s valuation and future iPhone demand.
T1 Energy Stock Gets a $32 Million Battery Test as AI Power Demand Builds

T1 Energy Stock Gets a $32 Million Battery Test as AI Power Demand Builds

3 June 2026
T1 Energy shares held nearly flat after announcing a $32 million deal to acquire KORE Power, expanding into battery storage and data-center infrastructure; Northland initiated coverage with an Outperform rating and $16 price target but highlighted funding and ramp-up risks, as T1 aims for positive EBITDA in 2026 and $15–20 million EBITDA contribution in 2027, pending deal closure and KORE shareholder approval.
Grab Shares Slide After Q1 Beat, Investors Eye Market Headwinds

Grab Shares Slide After Q1 Beat, Investors Eye Market Headwinds

3 June 2026
Grab shares slid 5.7% to $3.395 in heavy Nasdaq trading, underperforming after strong Q1 results with revenue up 24% and adjusted EBITDA up 46%, as investors worried about rising fuel costs, Indonesia’s planned commission cap, and broader market weakness driven by Middle East tensions and higher oil prices.
Sigma Healthcare share price drops: what investors are watching before Feb 26 results
Previous Story

Sigma Healthcare share price drops: what investors are watching before Feb 26 results

DBS share price dips after profit miss as dividend returns stay in focus
Next Story

DBS share price dips after profit miss as dividend returns stay in focus

Go toTop